Oak Asset Management LLC Purchases Shares of 2,295 Regeneron Pharmaceuticals Inc (NASDAQ:REGN)

Oak Asset Management LLC purchased a new stake in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 2,295 shares of the biopharmaceutical company’s stock, valued at approximately $681,000.

Several other large investors have also recently made changes to their positions in the business. Smithfield Trust Co. acquired a new position in shares of Regeneron Pharmaceuticals during the first quarter valued at approximately $27,000. Harel Insurance Investments & Financial Services Ltd. acquired a new position in shares of Regeneron Pharmaceuticals during the first quarter valued at approximately $29,000. Citizens Financial Group Inc RI acquired a new position in shares of Regeneron Pharmaceuticals during the first quarter valued at approximately $30,000. Accurate Investment Solutions Inc. acquired a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at approximately $31,000. Finally, Thor Advisors LLC acquired a new position in shares of Regeneron Pharmaceuticals during the first quarter valued at approximately $32,000. Institutional investors own 66.95% of the company’s stock.

In related news, Director Joseph L. Goldstein sold 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 15th. The shares were sold at an average price of $305.93, for a total value of $305,930.00. Following the completion of the transaction, the director now owns 11,323 shares of the company’s stock, valued at approximately $3,464,045.39. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Neil Stahl sold 9,853 shares of the firm’s stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $305.74, for a total transaction of $3,012,456.22. Following the completion of the transaction, the executive vice president now directly owns 47,450 shares of the company’s stock, valued at approximately $14,507,363. The disclosure for this sale can be found here. Company insiders own 11.84% of the company’s stock.

NASDAQ:REGN traded down $0.97 during trading hours on Tuesday, reaching $298.60. 57,205 shares of the company’s stock were exchanged, compared to its average volume of 803,154. The stock has a market cap of $33.36 billion, a P/E ratio of 15.02, a P/E/G ratio of 1.43 and a beta of 1.15. Regeneron Pharmaceuticals Inc has a 12 month low of $287.66 and a 12 month high of $442.00. The company has a debt-to-equity ratio of 0.08, a current ratio of 4.58 and a quick ratio of 3.78. The stock has a 50-day moving average price of $306.75.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported $4.45 EPS for the quarter, missing analysts’ consensus estimates of $5.24 by ($0.79). Regeneron Pharmaceuticals had a return on equity of 26.95% and a net margin of 35.13%. The firm had revenue of $1.71 billion during the quarter, compared to analyst estimates of $1.76 billion. During the same period in the prior year, the business posted $4.67 EPS. The company’s revenue for the quarter was up 13.3% on a year-over-year basis. On average, sell-side analysts forecast that Regeneron Pharmaceuticals Inc will post 18.37 EPS for the current year.

A number of research analysts recently commented on REGN shares. Jefferies Financial Group lowered their price objective on shares of Regeneron Pharmaceuticals from $376.00 to $343.00 and set a “hold” rating on the stock in a research note on Wednesday, April 17th. Credit Suisse Group started coverage on shares of Regeneron Pharmaceuticals in a research note on Monday, May 20th. They set a “neutral” rating and a $336.00 price objective on the stock. JPMorgan Chase & Co. reiterated a “hold” rating on shares of Regeneron Pharmaceuticals in a research note on Friday, June 21st. BMO Capital Markets lowered their price objective on shares of Regeneron Pharmaceuticals from $412.00 to $375.00 and set a “market perform” rating on the stock in a research note on Wednesday, May 8th. Finally, Cowen reiterated a “hold” rating and set a $353.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Monday, July 29th. Three research analysts have rated the stock with a sell rating, twelve have issued a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $394.31.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

See Also: What are the benefits of a balanced fund?

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.